Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,019,615,488
  • Shares Outstanding, K 945,384
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 19,815 M
  • EBITDA $ 21,582 M
  • 60-Month Beta 0.35
  • Price/Sales 16.35
  • Price/Cash Flow 73.15
  • Price/Book 41.27

Options Overview Details

View History
  • Implied Volatility 38.89% (-0.79%)
  • Historical Volatility 28.75%
  • IV Percentile 67%
  • IV Rank 34.83%
  • IV High 64.53% on 04/07/25
  • IV Low 25.20% on 02/06/25
  • Expected Move (DTE 1) 14.20 (1.31%)
  • Put/Call Vol Ratio 0.71
  • Today's Volume 26,482
  • Volume Avg (30-Day) 37,665
  • Put/Call OI Ratio 1.03
  • Today's Open Interest 302,777
  • Open Int (30-Day) 366,834
  • Expected Range 1,067.88 to 1,096.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 7.42
  • Number of Estimates 7
  • High Estimate 8.72
  • Low Estimate 6.51
  • Prior Year 5.32
  • Growth Rate Est. (year over year) +39.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,012.57 +6.81%
on 01/15/26
1,133.95 -4.62%
on 01/08/26
+5.03 (+0.47%)
since 12/22/25
3-Month
806.02 +34.18%
on 10/23/25
1,133.95 -4.62%
on 01/08/26
+269.08 (+33.12%)
since 10/22/25
52-Week
623.78 +73.38%
on 08/08/25
1,133.95 -4.62%
on 01/08/26
+327.53 (+43.44%)
since 01/22/25

Most Recent Stories

More News
ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Eli Lilly and Company (“Eli Lilly”)...

LLY : 1,082.65 (+0.38%)
The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1?

Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?

NVO : 62.03 (+4.57%)
JPM : 306.98 (+1.64%)
LLY : 1,082.65 (+0.38%)
Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

INDIANAPOLIS , Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference...

LLY : 1,082.65 (+0.38%)
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026

These three biotech stocks combine scale, late-stage pipelines, and analyst confidence, giving investors compelling upside potential in 2026

VKTX : 34.13 (+2.25%)
LLY : 1,082.65 (+0.38%)
BIIB : 173.90 (+0.74%)
Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

INDIANAPOLIS , Jan. 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart...

LLY : 1,082.65 (+0.38%)
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

VKTX : 34.13 (+2.25%)
AZN : 91.56 (+1.13%)
OZEM : 36.72 (+1.75%)
NVO : 62.03 (+4.57%)
LLY : 1,082.65 (+0.38%)
REGN : 758.22 (+1.19%)
AMGN : 348.11 (+1.31%)
PFE : 26.06 (+0.66%)
Stocks Boosted by Chip Demand Optimism

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.60%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.32%. March E-mini...

MSTR : 162.46 (-0.82%)
BLK : 1,145.66 (+1.58%)
AMAT : 322.25 (-0.92%)
MPC : 176.56 (-0.52%)
SNDK : 492.14 (-1.83%)
ADI : 308.25 (+1.08%)
MLTX : 16.40 (-1.86%)
$IUXX : 25,534.02 (+0.82%)
COIN : 225.46 (-0.65%)
ASML : 1,378.88 (+1.38%)
ZNH26 : 111-170 (-0.11%)
OXY : 42.89 (-1.42%)
Why Eli Lilly (LLY) Stock Is Down Today

Why Eli Lilly (LLY) Stock Is Down Today

LLY : 1,082.65 (+0.38%)
Stocks Supported by Strength in Chip Makers and US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.49%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.07%. March E-mini S&P futures (ESH26...

BLK : 1,145.66 (+1.58%)
MSTR : 162.46 (-0.82%)
AMAT : 322.25 (-0.92%)
MPC : 176.56 (-0.52%)
SNDK : 492.14 (-1.83%)
ADI : 308.25 (+1.08%)
MLTX : 16.40 (-1.86%)
$IUXX : 25,534.02 (+0.82%)
ASML : 1,378.88 (+1.38%)
ZNH26 : 111-170 (-0.11%)
OXY : 42.89 (-1.42%)
ESH26 : 6,961.00 (+0.74%)
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors...

ONCY : 1.2502 (+6.85%)
BCT.TO : 6.04 (+3.60%)
ACRV : 2.05 (-1.91%)
LLY : 1,082.65 (+0.38%)
BCTX : 4.39 (+4.28%)
GLSI : 25.38 (+13.81%)
CATX : 2.67 (+4.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,131.87
2nd Resistance Point 1,106.60
1st Resistance Point 1,092.56
Last Price 1,082.65
1st Support Level 1,053.25
2nd Support Level 1,027.98
3rd Support Level 1,013.94

See More

52-Week High 1,133.95
Last Price 1,082.65
Fibonacci 61.8% 939.07
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar